Opdivo (nivolumab) FDA Approval History - Drugs.com
Oct 6, 2024 · Approval FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and …
FDA approves nivolumab and hyaluronidase-nvhy for …
On December 27, 2024, the Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb Company) for subcutaneous …
FDA approves neoadjuvant nivolumab and platinum-doublet …
On March 4, 2022, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) with platinum-doublet chemotherapy for adult patients with resectable non …
FDA approves nivolumab for adjuvant treatment of Stage IIB/C …
On October 13, 2023, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for the adjuvant treatment of completely resected Stage IIB/C …
FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable
On 3 October 2024, the US Food and Drug Administration (FDA) approved nivolumab (Opdivo, Bristol Myers Squibb Company) with platinum-doublet chemotherapy as neoadjuvant …
FDA Approves Nivolumab for the Treatment of Adult Patients …
Oct 4, 2024 · The FDA has approved nivolumab (Opdivo; Bristol Myers Squibb) for the treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer …
Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA
Oct 4, 2024 · The FDA has approved nivolumab (Opdivo; Bristol Myers Squibb) for adult patients who are node positive or have resectable non–small cell lung cancer (NSCLC) tumors that are …
FDA Approves Perioperative Nivolumab for Resectable NSCLC
On October 3, 2024, the U.S. Food and Drug Administration approved nivolumab (Opdivo) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab …
FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable …
On October 3, 2024, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with platinum-doublet chemotherapy as neoadjuvant treatment, …
FDA Approves Subcutaneous Nivolumab in Advanced or …
Dec 27, 2024 · Subcutaneous nivolumab is approved for multiple solid tumors, excluding use with intravenous ipilimumab, offering a new administration route for patients. The CHECKMATE …